Sight Sciences announced FDA 510(k) clearance for its OMNI Ultra Surgical System, a minimally invasive glaucoma surgery (MIGS) device designed for single pass canaloplasty and trabeculotomy to reduce intraocular pressure in adults with primary open-angle glaucoma. The OMNI Ultra offers implant-free intervention addressing all three areas of aqueous outflow resistance through a single microincision, featuring TruSync Plus technology for enhanced control and precision. This clearance marks a significant advancement in glaucoma treatment, with the commercial launch planned for Q4 2026. The device supports both standalone and combined cataract surgeries, aiming to improve surgical outcomes and patient care.
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
State Street reported its Q3 2026 earnings with adjusted EPS of $3.69, slightly above the $3.68 estimate, marking its fourth consecutive quarterly earnings beat. Revenue rose 13% year-over-year to about $4 billion but missed analyst expectations of $...
